Gustave Roussy is the first leader cancer-research hospital in Europe and ranked among the top 5 best specialized hospitals in the world. It is a centre for high quality patient care, research and teaching. It is highly-known for the treatment of: skin cancers like melanoma, breast cancer, and lung cancer.

There are 457 beds in Institute Gustave Roussy.

During the past decade, Institute Gustave Roussy conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 3 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 1 clinical trials were completed. i.e. 11.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute Gustave Roussy" #1 sponsor was "CellCentric Ltd." with 2 trials, followed by "Cytovation AS" with 2 trials sponsored, "Nuvalent Inc." with 2 trials sponsored, "AGO Study Group" with 1 trials sponsored and "Adaptimmune" with 1 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute Gustave Roussy" #1 collaborator was "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Agendia" with 1 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 1 trials as a collaborator, "Exystat" with 1 trials as a collaborator and "Genzyme, a Sanofi Company" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Institute Gustave Roussy" are "Breast Cancer" (2 trials), "Locally Advanced Solid Tumor" (2 trials), "Metastatic Solid Tumor" (2 trials), "AFP Expressing Tumors" (1 trials) and "Acute Myeloid Leukemia" (1 trials). Many other conditions were trialed in "Institute Gustave Roussy" in a lesser frequency.

Most popular intervention types in "Institute Gustave Roussy" are "Drug" (16 trials), "Other" (2 trials), "Procedure" (2 trials), "Device" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "CCS1477" (2 trials), "CyPep-1" (2 trials), "3 cycles of standard chemotherapy" (1 trials), "6 cycles of standard chemotherapy" (1 trials) and "ADU-1604" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institute Gustave Roussy" are 16 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Institute Gustave Roussy". undefined are not yet recruiting, 10 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Institute Gustave Roussy, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Institute Gustave Roussy, 11 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".